---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-041975"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:54:38.855392+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# IN8bio appoints COO Kate Rochlin as President, effective immediately

## Summary
- Kate Rochlin, current COO, assumes additional role of President effective Feb. 4, 2026.
- Dr. Rochlin will continue serving as Chief Operating Officer of IN8bio.
- Appointment made by Board on Feb. 4, 2026; no other executive changes.
- No family relationships or transactions requiring disclosure under Regulation S-K.

## SEC filing metadata
- accession: 0001193125-26-041975
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312526041975/0001193125-26-041975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312526041975/d50284d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-041975
- JSON: https://secwatch.observer/filing/0001193125-26-041975.json
- Plain text: https://secwatch.observer/filing/0001193125-26-041975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.